Bermack Jordanna E, Haddjeri Nasser, Debonnel Guy
Department of Psychiatry, McGill University, 1033 Pine Avenue West, Montréal, Québec, Canada H3A 1A1.
J Pharmacol Exp Ther. 2004 Aug;310(2):578-83. doi: 10.1124/jpet.104.066472. Epub 2004 Mar 24.
OPC-14523 (OPC; [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate)] is a novel compound with high affinity for sigma and 5-HT(1A) receptors as well as for the 5-HT transporter. OPC has previously been shown to produce antidepressant-like effects in animal models of depression. This project set out to determine the effect of OPC on serotonergic neurotransmission and to shed light on its mechanism(s) of action. In an electrophysiological model of in vivo extracellular recordings in anesthetized rats, a 2-day treatment (1 mg/kg/day) with OPC induced a significant increase in dorsal raphe nucleus (DRN) putative 5-HT neurons' firing activity. This increase was blocked by the coadministration of NE-100 [N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)-thylamine], a selective sigma(1) antagonist (10 mg/kg/day). Furthermore, after 2-day treatments with OPC, the 5-HT(1A) autoreceptor response was altered, as demonstrated by the dramatically reduced response to an increase of endogenous 5-HT induced by the acute administration of paroxetine (500 microg/kg, i.v.). However, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (4 microg/kg, i.v.) maintained its ability to decrease 5-HT firing activity, an effect that was reversible by the subsequent administration of the 5-HT(1A) antagonist WAY 100635 [N-[2-(4-[2-methoxyphenyl]-1-piperazinyl)ethyl]-N-2-pyridinylcyclohexanecarboxamide] (100 microg/kg, i.v.). As 8-OH-DPAT has been shown to act preferentially through postsynaptic 5-HT(1A) receptors, our data suggests that this effect of OPC is mediated primarily by the 5-HT(1A) autoreceptor. The decreased response of the 5-HT(1A) autoreceptor to paroxetine was not blocked by the coadministration of NE-100 indicating that sigma(1) receptors are not involved in this effect. Thus, both sigma and 5-HT(1A) receptors play a role in the "antidepressant-like" effects produced by OPC, which is in keeping with previously published behavioral data. In addition, the current series of experiments suggest that OPC might have potential as an antidepressant with a rapid onset of action compared with selective serotonin reuptake inhibitor treatments, which initially suppress the firing activity of putative 5-HT neurons and require at least 2 to 3 weeks to restore the firing activity to baseline neuronal firing activity through a desensitization of the 5-HT(1A) autoreceptor.
OPC - 14523(OPC;[1 - [3 - [4 - (3 - 氯苯基) - 1 - 哌嗪基]丙基] - 5 - 甲氧基 - 3,4 - 二氢 - 2 - 喹啉酮甲磺酸盐])是一种对σ受体、5 - HT(1A)受体以及5 - HT转运体具有高亲和力的新型化合物。此前已证明OPC在抑郁症动物模型中产生类似抗抑郁的作用。本项目旨在确定OPC对5 - 羟色胺能神经传递的影响,并阐明其作用机制。在麻醉大鼠体内细胞外记录的电生理模型中,连续2天给予OPC(1毫克/千克/天)可使中缝背核(DRN)假定的5 - HT神经元放电活动显著增加。这种增加被共同给予的NE - 100 [N,N - 二丙基 - 2 - (4 - 甲氧基 - 3 - (2 - 苯乙氧基)苯基) - 乙胺](一种选择性σ(1)拮抗剂,10毫克/千克/天)所阻断。此外,在用OPC进行2天治疗后,5 - HT(1A)自身受体反应发生改变,这表现为对帕罗西汀(500微克/千克,静脉注射)急性给药诱导的内源性5 - HT增加的反应显著降低。然而,5 - HT(1A)激动剂8 - 羟基 - 2 - (二正丙基氨基)四氢萘(8 - OH - DPAT)(4微克/千克,静脉注射)仍保持其降低5 - HT放电活动的能力,随后给予5 - HT(1A)拮抗剂WAY 100635 [N - [2 - (4 - [2 - 甲氧基苯基] - 1 - 哌嗪基)乙基] - N - 2 - 吡啶基环己烷甲酰胺](100微克/千克,静脉注射)可使该作用逆转。由于已证明8 - OH - DPAT主要通过突触后5 - HT(1A)受体起作用,我们的数据表明OPC的这种作用主要由5 - HT(1A)自身受体介导。5 - HT(1A)自身受体对帕罗西汀反应的降低未被共同给予NE - 100所阻断,表明σ(1)受体不参与此作用。因此,σ受体和5 - HT(1A)受体在OPC产生的“类似抗抑郁”作用中均发挥作用,这与先前发表的行为学数据一致。此外,当前系列实验表明,与选择性5 - 羟色胺再摄取抑制剂治疗相比,OPC可能具有快速起效的抗抑郁潜力,选择性5 - 羟色胺再摄取抑制剂治疗最初会抑制假定的5 - HT神经元的放电活动,并且需要至少2至3周才能通过5 - HT(1A)自身受体的脱敏将放电活动恢复到基线神经元放电活动水平。